Joe’s Jeans Inc. (JOEZ) designs, produces and sells apparel and apparel-related products to the retail and premium markets under the Joe’s® brand and related trademarks. Its productline includeswomen’s, men’s, and children’s denim jeans, pants, shirts, sweaters, jackets, and other apparel products under the Joe’s brand. The company also offershandbags, clutches, belts, and small leather goods under a license agreement. It sells its products to variousretailers, including department stores, specialty stores, and distributors, as well as through its retail stores. As of May, 2010, Joe’s Jeans Inc. operated 13 full price retail stores in Chicago, Illinois; and San Francisco, California, Washington D.C, Boston, Cincinnati as well as 4outlet stores in outlet centers.
JOEZ stock is up more than 70% year-to-date thanks to strong revenue and sales. In spite of its premium garments with expensive prices, Joes Jeans has turned a quarterly profit in each of the last four periods — including fourth-quarter profit that topped Wall Street estimates by 400%! That’s earnings growth you can take to the bank, making JOEZ a great penny stock to buy now.
It is a Stock with a lot of growth potential and relatively low priced right now.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) recently announced that it anticipates initiating multi-national, Phase 3 trial of voreloxin in the second half of 2010. What could be the target price of Sunesis Pharmaceuticals (SNSS) if Voreloxin is approved? Let’s evaluate SNSS for this purpose.
Biotech Stock Evaluation involves analyzing the different points. A fair evaluation is to be made before investing in any biotech stocks.
1. Competitor (Existing and other drugs in the Pipeline) : Voreloxin is used for treating Acute Myeloid Leukemia. CYCC is is the main competitor for SNSS. Sapacitabine (CYC682) is also in the Phase II trial stage. What will be the market share of Voreloxin? This will depend of the performance of CYC682 and Voreloxin. However if the drug is approved, we can count on at least 30% market share. (If the drug is so bad, then FDA will not approve the drug.)
2. Market for the drug. : AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The National Cancer Institute estimated that nearly 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. in 2009. Additionally, it is estimated that prevalence of AML is approximately 25,000 in the U.S. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. Estimated AML market is $900mm a year. 30% of 900mm = 270mm
3. No of Shares outstanding.: 110mm shares outstanding as of today. By the time the drug is approved, number of shares is most likely to go up to another 25% (to be safe). So for our calculations we will consider 110 * 1.25 = 137.5 mm
4. Gross margin: 40 % to be fair
270 * .4 = 108
5. Operating expenses: 50mm per year for new trial and research expense.
6. Profit after operating expense 108 – 50 = 58 million
7. Assume a P/E ration of 20 gives = $1.16billion
8. Price per Share will be 1160/ 137.5 = 8.43
9.Now what is the chance of approval, taking a 50% chance of FDA approval will bring the value down to $4.215.
10. Approval will be at least 2 year away. For each year discount at least 20%.
4.215 – .843 = 3.372
3.372 – .6744 = 2.69
So we have calculated targeted value as $8.43. However we can say that now it is $2.5 stock.
Note: We take no responsibility for the loss or gain made by individual investor. Investors should do their own research before investing the money in the stock.
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) recently announced that it anticipates initiating multi-national, Phase 3 trial of voreloxin in the second half of 2010. Sunesis completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) related to its lead compound, voreloxin, in acute myeloid leukemia (AML). Sunesis has received feedback and guidance from the FDA in response to proposed plans for further development of voreloxin in the treatment of AML. Based on the development clarity achieved as a result of these meetings, Sunesis intends to proceed with its plan to conduct a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. This trial will evaluate the overall survival of voreloxin in combination with cytarabine, a widely used chemotherapy in AML, compared to cytarabine with placebo, in patients with relapsed or refractory AML.
Sunesis also reported today that, as part of its global development strategy, a pre-submission meeting has been scheduled for the current calendar quarter with the European Medicines Agency (EMA) to obtain EMA’s scientific advice on the development program for voreloxin, including the proposed Phase 3 trial.
“We are very pleased by the outcomes of these milestone meetings with the FDA and are looking forward to initiating our multi-national Phase 3 trial,” stated Daniel Swisher, Chief Executive Officer of Sunesis. “We believe that voreloxin’s novel anti-leukemic properties and encouraging Phase 2 clinical data hold significant potential in a patient population with few treatment options. As we evaluate how best to fund our voreloxin development program, including our planned Phase 3 trial, we are continuing discussions with potential pharmaceutical partners.”
Matthew Brown, founder of the Investors Hub website, pleaded guilty this week to securities fraud for his role in pump-and-dump schemes involving four different penny stocks, StockWatch has reported. Together with six other defendants, StockWatch said, Brown allegedly manipulated the stocks through “prearranged trades that were timed to coincide with misleading news and posts on Investors Hub” and then dumped the inflated shares.
Read more...
Categories:
Investing, Penny Stock Tags:
- Be anonymous
- Use 10% fact. 90% suggestion. The facts will lend credibility to your suggestions.
- Let others help you learn about the stock. Build rapport and a support base before initiating your Bashing routine.
- Enter with humor and reply to all who reply to you.
- Use multiple ISP’s, handles and aliases.
- Use two (2) or more aliases to simulate a discussion.
- Do not
start with an all out slam of the stock. Build softly.
- Identify your foes (Longs) and the boards “guru” Use them to
your advantage. Lead them do not follow their lead.
- Only Bash until the tide/momentum turns. Let doubt carry it the rest of the way.
- Give the appearance of being open minded.
- Be bold in your statements. People follow strength.
- Write headlines in caps with catchy statements.
- Pour it on as your position gains momentum. Not your personality.
- Don’t worry about being labeled a “Basher”. Newbies won’t know your history.
- When identified put up a brief fight, then back off. Return in an hour unless your
foe is a weak in reasoning powers.
- Your goal is to limit the momentum of the run. Not to tank the
company or create a plunge in the stock; be subtle and consistent.
- Kill the dreams of profits, not the company or the stock.
- Use questions to create critical thinking. Statements to reinforce facts.
- DO NOT LIE, NAME CALL or USE PROFANITY.
- Encourage people to call the company. 99% won’t. They’ll take your word for claims made. If they do call you can always find something that
is inaccurate in how they report their findings.
- Discourage people from believing Press Releases. Encourage them to call the company. They won’t out of laziness.
- If the companies history/PR’s are negative constantly point to that. Compile
a list of this data prior to beginning your efforts.
- If the price rises blame it on the hype or the PR, temporary mass reaction, the market, etc. Anything but the stock itself.
- If other posters share your concerns, play on that and share theirs too.
- Always cite low volume, even when it’s not.
- Three or four aliases can dominate a board and wear down the longs.
- Bait the Longs into personal debates putting their focus/efforts on you and not the stock or facts. Divert their attention from facts.
- Promote other stocks that would-be investors can turn to instead of the one your Bashing.
- 3Do not fall for challenges on the “values” of what you are doing, it’s a game and you are playing it with your own rules.
What are the factors of Fundamental Analysis of Penny Stock? Fair stock analyzis is a must before investing in any stock.
Fundamentals: To determine the health, quality, efficiency, and potential of a company.
Primary
- Increasing Profits
- Competitive Strength
- Little or No Debt
- Improving Financial Ratios
- Trades by Company Officers
- Company Buy-Back Plans
- Industry Conditions
- Political and Social Trends
- News and Company Announcements
- Alliances and Tie-Ups
- Institutional Ownership
Secondary
- Market Risk
- Industry Risk
- Competition
- Management / Board Changes
- Legal Action / Lawsuits
Best biotech stock can give more than 500% gain with in a short period. When we say Biotech Stocks most of you should be remembering the recent gains made some Biotech companies like HGSI and CTIC. Few months back CTIC was going below .05 cents and now it is riding at about $1.50.
Read more...
Online Share Brokers
Who is the best online broker? There are many factors to consider. We are comparing the performance of Online brokers. This table will be updated as more information is available.
1. OptionsXpress
- Fees/ Trade:
- Free Trade:
- Minimum Deposit:
- Withdrawal Fee:
- Contract Fee:
- Tech Support:
- Monthly Fee:
- Others:
- Website Speed:
- Website Userfriendly:
- Free Tools Available:
2. Zecco
- Fees/ Trade: $4.5
- Free Trade: 10 free trades monthly with $25,000 Asset or after 25 trades
- Minimum Deposit:
- Withdrawal Fee:
- Contract Fee:
- Tech Support:
- Monthly Fee:
- Others:
- Website Speed:
- Website Userfriendly:
- Free Tools Available:
3.ETRADE
4.SogoTrade
- Fees/ Trade: $3.00
- Free Trade: 100 free trades
- Minimum Deposit:
- Withdrawal Fee:
- Contract Fee:
- Tech Support:
- Monthly Fee:
- Others: Free virus scan
- Website Speed:
- Website Userfriendly:
- Free Tools Available:
5.TradeKing
- Fees/ Trade:
- Free Trade:
- Minimum Deposit:
- Withdrawal Fee:
- Contract Fee:
- Tech Support:
- Monthly Fee:
- Others:
- Website Speed:
- Website Userfriendly:
- Free Tools Available:
6. tradeMONSTER
- Fees/ Trade:
- Free Trade:
- Minimum Deposit:
- Withdrawal Fee:
- Contract Fee:
- Tech Support:
- Monthly Fee:
- Others:
- Website Speed:
- Website Userfriendly:
- Free Tools Available:
7.ShareBuilder
- Fees/ Trade: $4.00
- Free Trade:
- Minimum Deposit:
- Withdrawal Fee:
- Contract Fee:
- Tech Support:
- Monthly Fee:
- Others:
- Website Speed:
- Website Userfriendly:
- Free Tools Available:
8. FolioInvesting
- Fees/ Trade:
- Free Trade:
- Minimum Deposit:
- Withdrawal Fee:
- Contract Fee:
- Tech Support:
- Monthly Fee:
- Others:
- Website Speed:
- Website Userfriendly:
- Free Tools Available:
9.Scottrade
- Fees/ Trade: $7.00
- Free Trade:
- Minimum Deposit:
- Withdrawal Fee:
- Contract Fee:
- Tech Support:
- Monthly Fee:
- Others:
- Website Speed:
- Website Userfriendly:
- Free Tools Available:
10. Schwab
- Fees/ Trade:
- Free Trade:
- Minimum Deposit:
- Withdrawal Fee:
- Contract Fee:
- Tech Support:
- Monthly Fee:
- Others:
- Website Speed:
- Website Userfriendly:
- Free Tools Available:
Note: We are not responsible for any errors in the data. If you have any objections or suggestion please submit through the comments. Investors are advised not to take this as a bench mark. We are not liable for any decision taken by you because of this information. Please do your research for your safety.
Investing in penny stocks provides traders with the opportunity to dramatically increase their profits, however, it also provides an equal opportunity to lose your trading capital quickly. The low cost of Pink Sheet securities is the primary advantage that they offer. Investors who wish to get in on a new company at the onset can pick up stock for literally pennies. If a company does well and grows that initial investment can grow from pennies to much large dividends.
Read more...
Form 10K is the annual report filed by every company with a total capital of 100million. This gives a comprehensive summary of a public company’s performance. Although similarly named, the annual report on Form 10-K is distinct from the often glossy “annual report to shareholders”, which a company must send to its shareholders when it holds an annual meeting to elect directors (though some companies combine the annual report and the 10-K into one document). The 10-K includes information such as company history, organizational structure, executive compensation, equity, subsidiaries, and audited financial statements, among other information.
Companies with more than $10 million in assets whose securities are held by more than 500 owners must file annual and other periodic reports, regardless of whether the securities are publicly or privately traded. Smaller companies may use Form 10-KSB. If a shareholder requests a company’s Form 10-K, the company must provide a copy.
In addition to the 10-K, which is filed annually, a company is also required to file quarterly reports on Form 10-Q. Information for the final quarter of a firm’s fiscal year is included in the annual 10-K, so only three 10-Q filings are made each year. In the period between these filings, and in case of a significant event, such as a CEO departing or bankruptcy, a Form 8-K must be filed in order to provide up to date information.